Loading
A phase 3 trial of Avelumab, Talazoparib, Pemetrexed in ovarian cancer, run by Pfizer, active and no longer recruiting.
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing is a phase 3 interventional study registered as NCT05059522 by Pfizer, with 77 participants enrolled, started 2021-09-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib. Conditions listed: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Utomilumab, Avelumab.
Shares Utomilumab, Avelumab.
Shares Axitinib, Pfizer (incl. Seagen).
Shares Avelumab, Pfizer (incl. Seagen), Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Axitinib, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/